

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-55 (canceled).

Claim 56 (new): An antibody that specifically binds SEQ ID NO: 4, or a fragment of SEQ ID NO: 4 that deregulates mammary epithelial cellular growth.

Claim 57 (new): The antibody of claim 56, wherein the antibody is a monoclonal antibody.

Claim 58 (new): The antibody of claim 57, wherein the antibody is a humanized antibody.

Claim 59 (new): The antibody of claim 56, covalently linked to a toxin, radionucleotide, detectable label or drug.

Claim 60 (new): The antibody of claim 59, covalently linked to a toxin.

Claim 61 (new): The antibody of claim 59, covalently linked to a radionucleotide.

Claim 62 (new): The antibody of claim 59, covalently linked to a detectable label.

Claim 63 (new): The antibody of claim 56, wherein the antibody is a polyclonal antibody.

Claim 64 (new): The antibody of claim 56, wherein the antibody specifically binds to a polypeptide encoded by a cDNA deposited as ATCC Accession No. 97209 or as ATCC Accession No. 97030.

Claim 65 (new) : A kit, comprising
a container containing the antibody of claim 56.

Claim 66 (new): The kit of claim 62, further comprising
a container comprising a second antibody that specifically binds the antibody of claim 56, wherein the second antibody comprises a label.